Supernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR®
June 22 2016 - 4:30PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced the issuance on June 21, 2016 of a seventh
patent (number 9,370,525) by the United States Patent and Trademark
Office (USPTO) covering Oxtellar XR, its novel once-daily
extended-release oxcarbazepine product. The patent provides
protection for the product with expiration that is no earlier than
2027.
“This newly issued patent strengthens Oxtellar XR's overall
patent portfolio. We now have patent protection on Oxtellar XR
through seven issued U.S. patents and on Trokendi XR® through six
issued U.S. patents. We remain focused on continuing to build our
patent estate to provide our products with the protection they are
entitled to,” said Jack A. Khattar, President and CEO of
Supernus.
Supernus has several additional patent applications for
extended-release oxcarbazepine and extended-release topiramate
pending in other geographic regions.
About Oxtellar XR
Oxtellar XR is the first approved novel, oral once-daily
extended release formulation of oxcarbazepine for the treatment of
epilepsy. Oxtellar XR is an antiepileptic drug indicated for
adjunctive therapy in the treatment of partial seizures in adults
and in children 6 to 17 years of age. The product is available in
150mg, 300mg, and 600mg extended-release tablets.
For full prescribing and safety information click here.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company has two
marketed products for epilepsy, Oxtellar XR® (extended-release
oxcarbazepine) and Trokendi XR® (extended-release topiramate). The
Company is also developing several product candidates to address
large market opportunities in psychiatry, including SPN-810 for the
treatment of Impulsive Aggression in patients with ADHD and SPN-812
for the treatment of ADHD.
Forward Looking Statements
This press release contains forward-looking statements regarding
the Company's ability to defend and enforce its intellectual
property rights covering Oxtellar XR or Trokendi XR. Actual results
may differ materially from those in these forward-looking
statements as a result of various factors, including, but not
limited to, the ability of Supernus to finance potential litigation
and to prevail in any such proceeding to successfully defend its
intellectual property rights. For a further description of these
and other risks facing the Company, please see the risk factors
described in the Company's Annual Report Form 10-K that was filed
with the United States Securities and Exchange Commission
("Commission") on March 9, 2016 under the caption "Risk Factors"
and the updates to these risk factors in the Company's Quarterly
Report form 10-Q filed with the Commission on May 9, 2016.
Forward-looking statements speak only as of the date of this press
release, and the Company undertakes no obligation to update or
revise these statements, except as may be required by law.
CONTACT:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Sep 2023 to Sep 2024